Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Rose

Showing results (201-210 of 210) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 210 results.
European Journal of Haematology|November 22, 2007
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective studyJohn Porter, Renzo Galanello, Giuseppe Saglio, et al.
Blood|September 20, 2013
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disordersFrederik Damm, Virginie Chesnais, Yasunobu Nagata, et al.
Haematologica|January 19, 2019
Clinical and biological features in <i>PIEZO1</i>-hereditary xerocytosis and Gardos channelopathy: a retrospective series of 126 patientsVéronique Picard, Corinne Guitton, Isabelle Thuret, et al.
Antioxidants & Redox Signaling|November 21, 2013
Targeting chelatable iron as a therapeutic modality in Parkinson's diseaseDavid Devos, Caroline Moreau, Jean Christophe Devedjian, et al.
Haematologica|October 6, 2018
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromesSophie Park, Olivier Kosmider, Frédéric Maloisel, et al.
Rheumatology (Oxford, England)|September 10, 2015
Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective studyArsène Mekinian, Eric Grignano, Thorsten Braun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2017
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating AgentsSophie Park, Jean-François Hamel, Andrea Toma, et al.
Haematologica|June 15, 2023
Characterization of genetic variants in the <i>EGLN1/PHD2</i> gene identified in a European collection of patients with erythrocytosisMarine Delamare, Amandine Le Roy, Mathilde Pacault, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 1, 2013
S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short versionAnnette Pflugfelder, Corinna Kochs, Andreas Blum, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 14, 2013
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma"Annette Pflugfelder, Corinna Kochs, Andreas Blum, et al.
Pageof 21

Showing results (201-210 of 210) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 210 results.
European Journal of Haematology|November 22, 2007
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective studyJohn Porter, Renzo Galanello, Giuseppe Saglio, et al.
Blood|September 20, 2013
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disordersFrederik Damm, Virginie Chesnais, Yasunobu Nagata, et al.
Haematologica|January 19, 2019
Clinical and biological features in <i>PIEZO1</i>-hereditary xerocytosis and Gardos channelopathy: a retrospective series of 126 patientsVéronique Picard, Corinne Guitton, Isabelle Thuret, et al.
Antioxidants & Redox Signaling|November 21, 2013
Targeting chelatable iron as a therapeutic modality in Parkinson's diseaseDavid Devos, Caroline Moreau, Jean Christophe Devedjian, et al.
Haematologica|October 6, 2018
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromesSophie Park, Olivier Kosmider, Frédéric Maloisel, et al.
Rheumatology (Oxford, England)|September 10, 2015
Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective studyArsène Mekinian, Eric Grignano, Thorsten Braun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2017
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating AgentsSophie Park, Jean-François Hamel, Andrea Toma, et al.
Haematologica|June 15, 2023
Characterization of genetic variants in the <i>EGLN1/PHD2</i> gene identified in a European collection of patients with erythrocytosisMarine Delamare, Amandine Le Roy, Mathilde Pacault, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 1, 2013
S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short versionAnnette Pflugfelder, Corinna Kochs, Andreas Blum, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 14, 2013
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma"Annette Pflugfelder, Corinna Kochs, Andreas Blum, et al.
Pageof 21